Abstract:Idiopathic pulmonary fibrosis (IPF) is characterized by permanent scarring of lung tissue and declining lung function, and is an incurable disease with increase in prevalence over the past decade. The current consensus is that aberrant wound healing following repeated injuries to the pulmonary epithelium is the most probable cause of IPF, with various immune inflammatory pathways having been reported to impact disease pathogenesis. While the role of immune cells, specifically T lymphocytes and regulatory T cells (Treg), in IPF pathogenesis has been reported and discussed recently, the pathogenic or beneficial roles of these cells in inducing or preventing lung fibrosis is still debated. This lack of understanding could be due in part to the difficulty in obtaining diseased human lung tissue for research purposes. For this reason, many animal models have been developed over the years to attempt to mimic the main clinical hallmarks of IPF: among these, inducing lung injury in rodents with the anti-cancer agent bleomycin has now become the most commonly studied animal model of IPF. Pulmonary fibrosis is the major side effect when bleomycin is administered for cancer treatment in human patients, and a similar effect can be observed after intra-tracheal administration of bleomycin to rodents. Despite many pathophysiological pathways of lung fibrosis having been investigated in bleomycin-injured animal models, one central facet still remains controversial, namely the involvement of specific T lymphocyte subsets, and in particular Treg, in disease pathogenesis. This review aims to summarize the major findings and conclusions regarding the involvement of immune cells and their receptors in the pathogenesis of IPF, and to elaborate on important parallels between animal models and the human disease. A more detailed understanding of the role of Treg and other immune cell subsets in lung injury and fibrosis derived from animal models is a critical basis for translating this knowledge to the development of new immune-based therapies for the treatment of human IPF.

Regulatory T Cells Are a Double-Edged Sword in Pulmonary Fibrosis.

CD4+CD25+FoxP3+ Regulatory Tregs Inhibit Fibrocyte Recruitment and Fibrosis Via Suppression of FGF-9 Production in the TGF-Î²1 Exposed Murine Lung

Updates on the controversial roles of regulatory lymphoid cells in idiopathic pulmonary fibrosis

T cells in idiopathic pulmonary fibrosis: crucial but controversial

Regulation of idiopathic pulmonary fibrosis: a cross-talk between TGF- β signaling and MicroRNAs

Allies or enemies? The effect of regulatory T cells and related T lymphocytes on the profibrotic environment in bleomycin-injured lung mouse models

Pulmonary fibrosis: pathogenesis and therapeutic strategies

TGF2 and TGF3 isoforms drive fibrotic disease pathogenesis

Research Progress of Pericytes in Pulmonary Fibrosis

Imbalance of dendritic cell function in pulmonary fibrosis

Toll-like receptors in the pathogenesis of pulmonary fibrosis

Regulatory T cells (Tregs) in liver fibrosis

Regulatory T Cells: An Emerging Player in Radiation-Induced Lung Injury

The Role of Regulatory T Cells in Pulmonary Arterial Hypertension

miR-627/HMGB1/NF-κB regulatory loop modulates TGF-β1-induced pulmonary fibrosis.

Increased Activated Regulatory T Cells Proportion Correlate with the Severity of Idiopathic Pulmonary Fibrosis

TRAF6 Suppresses the Development of Pulmonary Fibrosis by Attenuating the Activation of Fibroblasts

TGF{beta} drives fibrotic remodeling via modulation of homeostatic and pathological fibroblast populations in a murine model of pulmonary fibrosis

Tocotrienol-Rich Fractions Offer Potential to Suppress Pulmonary Fibrosis Progression.

CCL17 Drives Fibroblast Activation in the Progression of Pulmonary Fibrosis by Enhancing the TGF-β/Smad Signaling.

Regulatory T cells in inflammation and resolution of acute lung injury